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At present, wt1, a Wilms’ tumor suppressor gene, is recognized as a critical regulator of tumorigenesis
and a potential therapeutic target. WT1 shows the ability to regulate the transcription of bcl-2 by binding
to a GC-rich region in the promoter, which can then fold into a special DNA secondary structure called
the G-quadruplex. This function merits the exploration of the effect of a G-quadruplex ligand on the
binding and subsequent regulation of WT1 on the bcl-2 promoter. In the present study, WT1 was found
to bind to the double strand containing the G-quadruplex-forming sequence of the bcl-2 promoter.
However, the G-quadruplex ligand SYUIQ-FM05 effectively blocked this binding by interacting with the
GC-rich sequence. Our new ﬁndings are signiﬁcant in the exploration of new strategies to block WT1's
transcriptional regulation for cancer-cell treatment.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The human Wilms' tumor 1 (wt1) gene, located at chromosome
11p13, was originally identiﬁed as a tumor suppressor in Wilms'
tumor in 1990 [1]. Because of its overexpression in hematologic
malignancies and a variety of solid cancers, but not in the healthy
adjacent tissues, wt1 is currently considered as a potential onco-
gene [2,3] and a promising target for cancer therapy. wt1 is a
prognostic biomarker in uterine sarcoma [4] and in acute myeloid
leukemia (AML) [5] because of its high correlation with cancer
growth and relapse. The knockdown of WT1 effectively induces
the apoptosis of leukemic cells [6] and inhibits malignant cell
growth [7]. WT1 peptide vaccination of clinical patients with
myeloid malignancies and several solid cancers has shown positive
outcomes [8]. All of the substantial investigations implicate WT1
as a critical regulator of tumorigenesis and a potential therapeutic
target.
The wt1 gene encodes a zinc-ﬁnger transcription factor that can
be translated into at least 36 isoforms by alternative mRNAB.V. This is an open access article u
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rescence resonance energy
, reverse transcription poly-
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Ou).
cript.splicing. All of these isoforms have four Cys2-His2 zinc ﬁngers on
their C-terminus [9]. The alternative splice sites at the end of exon
9 leads to the insertion of three amino acids (KTS) between zinc
ﬁngers 3 and 4, thereby forming two kinds of zinc-ﬁnger domains
termed as ZFKTS and ZFþKTS [10]. The ZFþKTS isoform usually
binds to RNA and tends to function in the post-transcriptional
regulatory processes [11], whereas the ZFKTS isoform binds to
DNA more strongly and is more active in transcriptional regulation
[12]. By recognizing the consensus site 5′–GNGNGGGNG–3′, WT1
was reported as a transcriptional regulator that targets at least 137
genes. As such, WT1 plays important roles in cell processes, in-
cluding cell differentiation, cell adhesion, apoptosis, angiogenesis,
and immune function [13,14]. Interestingly, the GC-rich sites re-
cognized by WT1 were reported to be remarkably associated with
the potential G-quadruplex-forming motifs, which carry a sig-
nature motif of GZ3NXGZ3NXGZ3NXGZ3NX, in humans, chim-
panzees, mice, and rats [15]. This observation implies the possible
role of WT1 in transcriptional regulation through G-quadruplex
elements. A well-known example is a 39 bp GC-rich element
(Pu39) located upstream of the P1 promoter of the bcl-2 oncogene
(Fig. 1). In our study, we select a native sequence Pu59 from the
bcl-2 promoter; Pu39 sequence locates in the center of Pu59 and a
10-nucleotide ﬂanking sequence was added on each side of Pu39.
This region can be bound directly by the WT1 protein and plays an
important role in the regulation of bcl-2 gene transcription [16].
This guanine-rich sequence also has the potential to form a
G-quadruplex structure and might cause the down-regulation ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. WT1 binding sites in the bcl-2 promoter and the G-quadruplex-forming sequence in the bcl-2 promoter. Two conservative binding sites of WT1 exist in the Pu59
region (red region). The binding of WT1 to the bcl-2 promoter will activate bcl-2 transcription. The Pu59 region (blue region) in the bcl-2 promoter bcl-2 can form a
G-quadruplex structure and be stabilized by compound SYUIQ-FM05. The resulting structure would lead to transcriptional arrest. The relationship among WT1, the Pu59
region, and the G-quadruplex ligand SYUIQ-FM05 will be further illustrated in this paper. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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ported possessing different functions, such as inhibition onco-
genes' transcription, interfering with the telomere's function, and
repressing tumor cell growth [17]. The high correlation between
the WT1 binding sites and the G-quadruplex-forming site was
noted. Hence, we explore whether or not WT1 can bind to the
G-quadruplex structure. The second reason for our research is
related to the positive roles that WT1 plays in leukemogenesis, in
which it promotes tumor cell survival and affect clinical outcomes
[18]. Moreover, bcl-2 is reported to be transcriptionally upregu-
lated by WT1 [19]. The coexpression of WT1 and BCL-2 is asso-
ciated with response and long-term outcome of AMLs [20].
Therefore, we attempt to study the mechanism of the compound
interfering with the transcriptional regulation of WT1.
In the present research, a variety of methods, including the
electrophoretic mobility shift assay (EMSA), ﬂuorescent studies,
isothermal titration calorimetry (ITC), chromatin im-
munoprecipitation (Ch-IP), and circular dichroism (CD) were ap-
plied. For the ﬁrst time, we demonstrated that WT1 cannot bind to
the G-quadruplex structure. We identiﬁed a G-quadruplex ligand
that could block WT1 binding by interaction with the GC-rich
region containing the G-quadruplex-forming sequence in the
promoter region of bcl-2 gene. These new ﬁndings are signiﬁcant
in the development of new strategies to block WT1's transcrip-
tional regulation for the treatment of leukemia cells.2. Materials and methods
2.1. Materials
All chemicals were obtained from commercial sources. All oli-
gomers were purchased from Invitrogen (China). The enzymes
used for reverse transcription and PCR were purchased from Ta-
KaRa (China), and the enzymes used for plasmid construction were
purchased from Fermentas (USA). The compound was synthesized
by our group as described previously [21] and was dissolved in
dimethyl sulfoxide (DMSO) at the concentration of 10 mM as the
stock solution. HL-60 (human promyelocytic leukemia cell lines)
were obtained from the American Type Culture Collection and
preserved at our laboratory. HL-60 cells were cultured in 1640
medium supplemented with 10% fetal bovine serum and 5% CO2 at
37 °C. The antibodies employed in the study include WT1 poly-
clonal antibody (sc-192, Santa Cruz, CA, USA) and anti-rabbit IgG–
horseradish peroxidase (#7074, Cell Signaling, MA, USA).2.2. Plasmid construction and protein puriﬁcation
Total mRNAs were isolated from the HL-60 cells using the
RNAiso Plus reagent (TaKaRa, China) following the manufacturer's
protocol. Then, 500 ng of total RNA was reverse transcribed in a
total volume of 20 μL PCR mixture using the M-MLV reverse
transcriptase (TaKaRa, China) and oligo d(T)18 primer (TaKaRa,
China). After reverse transcription, the cDNA was subjected to PCR
for the ampliﬁcation of the C-terminus of WT1 (amino acids 312–
449) containing the four zinc ﬁngers using primers ZF-A (5′–
GGAATTCTCAAAGCGCCAGCTGGAG–3′) and ZF-S (5′–GAATTCCA-
TATGTCGGCATCTGAGACCAG–3′). PCR was performed on a Bio-Rad
T100 Thermal Cycler using Dreamtaq PCR kit (Thermo Scientiﬁc).
The program proceeded as follows: initial denaturation at 95 °C for
10 min, followed by 30 cycles of denaturation, annealing, and ex-
tension (95 °C for 10 s, 58 °C for 30 s, and 72 °C for 1 min). The PCR
products were veriﬁed using a 2% agarose gel. The PCR products
digested by NdeI and EcoRI were inserted into a pET-28a (þ)
vector (Novagen, TX, USA) for pET28a-(ZFKTS) plasmid
construction.
All reconstructed plasmids were sequenced and conﬁrmed by
BLAST on NCBI.
The E. coli strain BL21 (DE3) cells were transformed with pET-
28a-(ZF-KTS) plasmid for overexpression and puriﬁcation of the
recombinant protein. Cells were ﬁrst grown at 37 °C in 0.2 l of LB
medium containing kanamycin (50 ng/mL) to an OD600 of
0.6 before addition of 0.1 mM IPTG to induce protein expression.
Cells were then grown at 15 °C for 18 h before harvested by cen-
trifugation. Cell pellet was resuspended in 40 mL of start buffer
(20 mM potassium phosphate, pH 7.4, 0.5 M NaCl) and lysed using
a SCIENTZ-II D sonicator (SCIENTZ). The insoluble debris was re-
moved by centrifugation, and the clear supernatant was used for
protein puriﬁcation after ﬁltered through a 0.45 μm ﬁlter. Protein
puriﬁcation was carried out using the Hi-Trap column (GE
Healthcare) according to the protocol supplied by the manu-
facturer. The puriﬁed protein fractions were ﬁltered and stored in
20 mM Tris, 100 mM KCl, 1 mM DTT, and 10% glycerol, pH 7.4. The
puriﬁed protein was identiﬁed by MALDI-TOF-TOF (Ultraﬂex TOF/
TOF Ⅲ) and Mascot Search and the purity were veriﬁed by SDS-
polyacrylamide gel electrophoresis.
2.3. Electrophoretic mobility shift assay (EMSA)
The oligomers were diluted from stock solution to the indicated
concentration in Tris–HCl buffer (10 mM, pH 7.4) with or without
100 mM KCl, and then annealed by heating to 95 °C for 5 min, and
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5′-GGCGGCGCGGAGGGGCGGGCGCGGGAGGAAGG
GGGCGGGACGGGGCTGTGGTGCCTGT-3′. The sequence of the mu-
tant Pu59 was 5′- GGCGGCGCGGAGGGGCGGGCGCAAAAGGAAG
GGGGCGGGAGCGG GGCTGTGGTGCCTGT-3′, whose binding site of
WT-1 was changed. Py59 or mutPy59 were the complementary
strands of Pu59 or mutant Pu59; ds59 or mutant ds59 was the
annealed mixture of Pu59 and Py59, or mutant Pu59 and mutPy59,
respectively. Subsequently, oligomers at indicated concentrations
were incubated with the compound or recombinant protein at
varying concentrations in EMSA binding buffer (20 mM HEPES,
2 mM DTT, 0.2 mg/mL BSA, 1% Triton X-100, 6% glycerol, pH 7.4)
with or without 100 mM KCl for 1 h at 37 °C. Cold excess compe-
titors (ds59 or mutant ds59) with 50-time amount of oligomers
were added before incubation. The ﬁnal volume was 20 μL. The
reaction products were separated on 8% or 16% native poly-
acrylamide gels at 70 V for 4 h at 0 °C in the presence of ice-cooled
0.5 TBE buffer. The gels were silver stained as described pre-
viously [22].
2.4. Chromatin immunoprecipitation (ch-IP) assay
Ch-IP was performed using the Agarose Ch-IP Kit (#26156,
Pierce, USA) following the manufacturer's protocol. After 24 h of
seeding about 2106 HL-60 cells in a 10 cm2 culture ﬂask with or
without the compound, the cells were ﬁxed with 1% formaldehyde
for 10 min and then lysed. Ch-IP-class WT1 primary antibody (sc-
192, Santa Cruz, CA, USA) was used to immunoprecipitate chro-
matin in the HL-60 cells. Meanwhile, anti-rabbit IgG was used for
mock immunoprecipitation, and the RNA polymerase II antibody
provided by the kit was used as the positive control. Ch-IP was
performed at 4 °C for 16 h, and the resulting immune complexes
were collected using protein A magnetic beads provided by the kit.
After extensive washing, the DNA was extracted from im-
munoprecipitated chromatin. Immunoprecipitated DNA samples
were used to amplify different regions upstream the transcrip-
tional starting site of bcl-2, or the other WT1 target gene Pecam-1
with PCR primers (Table S1). The internal control glyceraldehyde
3-phosphate dehydrogenase (GAPDH) primers were provided by
the kit. PCR was performed on a Bio-Rad T100 Thermal Cycler
using Dreamtaq PCR kit (Thermo Scientiﬁc, EU). The program was
as follows: initial denaturation at 95 °C for 10 min, followed by 30
cycles of denaturation, annealing, and extension (95 °C for 10 s,
58 °C for 30 s, and 72 °C for 1 min). The PCR products were sepa-
rated on a 3% agarose gel.
2.5. UV–vis spectroscopic studies
Absorption spectral titration experiments were performed on a
JASCO double beam recording spectrophotometer by maintaining
a constant concentration of the compound (30 μM) with the oli-
gomer at varying concentrations. Compound-DNA solutions were
allowed to incubate for 5 min before the spectra were recorded.
From the absorption data, the intrinsic binding constant, Kb, was
determined using the following equation [23]:
[ ] ( ε − ε ) = [ ] ( ε − ε )+ ( ε −ε ) ( )KDNA / DNA / 1/ 1a f b f b b f
where εa, εf, and εb are the apparent, free, and bound compound
extinction coefﬁcients, respectively. In the plots of [DNA]/(εaεf)
versus [DNA], Kb was given the ratio of slope to the intercept.
2.6. Fluorescence spectroscopic studies
The 5′–FAM (6-carboxyﬂuorescein) and 3′–TAMRA (tetra-
methylrhodamine) dual-labeled bcl-2 Mid oligomer (5′–
GGGCGCGGGAGGAAGGGGGCGGG–3′) at a ﬁnal concentration of50 nM was incubated at 37 °C for 1 h with the puriﬁed WT1 pro-
tein at varying concentrations in ﬂuorescence resonance energy
transfer (FRET) binding buffer (20 mM HEPES, 2 mM dithiothreitol
[DTT], 0.2 mg/mL bovine serum albumin [BSA], 1% Triton X-100,
and 6% glycerol at pH 7.4) with or without 0.1 M KCl. The mixtures
were applied to a Perkin-Elmer LS-55 luminescence spectro-
photometer at 37 °C. A quartz cuvette with a 1 cm path length was
used to obtain the spectra at 10 nm excitation and emission slit
width. Fluorescence measurements were obtained at 480 nm ex-
citation. The ﬂuorescence-emission data points (from 500 nm to
650 nm) at each step were then recorded.
2.7. Circular dichroism (CD) spectroscopy
The oligomers at 5 μM ﬁnal concentration were resuspended in
CD binding buffer (10 mM Tris–HCl, and 0.1 M KCl at pH 7.4) with
various amounts of the compound and incubated for 5 min at
25 °C. The CD spectra were documented on a Chirascan CD spec-
trophotometer (Applied Photo-physics, UK) at 25 °C. A quartz
cuvette with a 4 mm path length was used in the process over a
wavelength range of 230–400 nm at 1 nm bandwidth, 1 nm step
size, and 0.5 s time per point. A buffer baseline was collected in the
same cuvette and subtracted from the sample spectra. Final ana-
lysis of the data was performed using Origin 8.0 (OriginLab Corp.).3. Results
3.1. WT1 binds to the GC-rich double-stranded region containing the
G-quadruplex-forming sequence in the bcl-2 promoter
The high correlation between WT1 binding sites and G-quad-
ruplex-forming site compelled us to explore the relationship be-
tween WT1 and the G-quadruplex-forming sequence in the bcl-2
promoter region. The zinc-ﬁnger domain ZFKTS is the key DNA
recognition element of WT1 that binds to the bcl-2 promoter and
is effective in transcriptional regulation. Thus, we cloned the
ZFKTS domain and manipulated ZFKTS in E. coli (Fig. S1). Pu59
was a G-rich DNA single strand of bcl-2 and can form G-quad-
ruplex structure, which was identiﬁed by using CD and ELISA (Fig.
S2). As shown in Fig. S2A, the CD spectra of Pu59 exhibited typical
parallel G-quadruplex signal with a positive peak at 262 nm and a
negative peak at 240 nm. ELISA was also performed using
G-quadruplex speciﬁc antibody BG4 [24]; the absorption at
450 nm could be used to identify the binding between BG4 and
the nucleotide. As shown in Fig. S2B, Pu59 could signiﬁcantly bind
with BG4, indicating that this sequence could form G-quadruplex
structure. Py59 was the corresponding C-rich complementary se-
quence and used to annealed with Pu59 to form the double-
stranded structure. We found that ZFKTS could bind to the
double-stranded DNA in a dose-dependent manner (Fig. 2, line 1–
4), but it did not bind to the Pu59 sequence (Fig. 2, line 7 and 8) or
the Py59 sequence (Fig. 2, line 9 and 10). The addition of cold
excess competitors was used to further identify the speciﬁcity of
the binding. As shown in line 5 and 6 in Fig. 2, excess ds59 could
reduce the amount of bound DNA while mutant ds59 could not
show this effect, indicating that the binding between ZF-KTS and
ds59 was speciﬁc. Moreover, the results from the FRET assay
showed no change in the secondary structure of the G-rich se-
quence mid-G in the presence of WT1 (Fig. 3). Regardless of se-
quence, the G-quadruplex structure would still form in the pre-
sence of KCl or would not (in the absence of KCl). From the results
of ELISA (Fig. S2B), the binding of BG4 to ds59 could still be de-
tected while reduced comparing with the binding between BG4
and Pu59, implying G-quadruplex might form in this region. The
results illustrated that ZFKTS could only recognize and bind to
Fig. 2. EMSA for the binding of WT1 ZFKTS to bcl-2 double-stranded Pu59
without any competitor (lines 1–4) or with competitors (lines 5 and 6), Py59 (lines
7 and 8), and Pu59 (lines 9 and 10). Different oligomers (60 pmol) were incubated
with the puriﬁed ZFKTS protein at varying concentrations and separated by 16%
native polyacrylamide gel electrophoresis (PAGE). Cold excess competitors (ds59 or
mutant ds59) with 50-time amount of oligomers were added before incubation.
The migration positions of the free and bound DNAs were indicated.
Fig. 3. FRET spectroscopy for the DNA secondary structure in the presence of WT1
zinc ﬁngers. Mid G4: Mid sequence in 10 mM Tris–HCl buffer (pH 7.4) containing
100 mM KCl; s-mid-G: Mid sequence in 10 mM Tris–HCl buffer (pH 7.4). r re-
presents the molar ratio of protein/DNA.
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the bcl-2 promoter, despite the secondary structure of the single-
stranded DNA. However, whether the structural changes inside the
WT1's binding sites, including the change in the duplex or the
change in one of the strands, would inﬂuence WT1 binding re-
mains unclear. We then performed the following experiments to
address this issue.
3.2. Blocking WT1 binding with small molecule SYUIQ-FM05
To further verify the relationship between WT1 and the
G-quadruplex structure, a quindoline derivative SYUIQ-FM05 was
used, which was identiﬁed as a G-quadruplex stabilizer. The
binding between ZFKTS and ds59 DNA could be blocked by
SYUIQ-FM05 in a dose-dependent manner (Fig. 4A, lines 2–5). On
the other hand, this interfering effect could not be detected with
the addition of ethidium bromide (EB), which is a conventional
DNA-intercalating agent (Fig. 4A, lines 6–9). This result implies
that SYUIQ-FM05 could speciﬁcally block the binding of WT1, and
the interaction may not involve EB.
Based on the results, Ch-IP assay was conducted to identify the
binding between WT1 and the bcl-2 promoter at the cellular level.
The human promyelocytic leukemia cell line (HL-60) with high
WT1 expression was used. The primers that can amplify the GC-rich
regions upstream of the transcription starting site were employedto detect the binding of WT1 to the GC-rich regions in the HL-60
cells. WT1 showed the most effective binding ability to the region
from 1443 to 1636, which contains the G-quadruplex-forming
sequence. No binding to other GC-rich regions was found (Fig. S3).
Therefore, we chose this region for further investigation. As shown
in Fig. 4B, the binding of WT1 weakened when cells were treated
with 0.2 μM SYUIQ-FM05, but the WT1 expression level was
maintained, as indicated by the Western blot (Fig. S4). The binding
of RNA polymerase II to the GAPDH gene fragment, and the binding
of WT1 to the other WT1 target gene Pecam-1 [14], were not af-
fected by the compound. This result indicated that the WT1 suc-
cessfully bound to the region containing the G-quadruplex-forming
sequence, and that SYUIQ-FM05 effectively blocked the binding of
WT1 to the bcl-2 promoter in the HL-60 cells.
3.3. SYUIQ-FM05 can effectively interact with the bcl-2 promoter
Pu59 region
In a previous study, SYUIQ-FM05 was identiﬁed as a G-quad-
ruplex ligand and exhibited strong binding afﬁnity and stabilizing
ability to the G-quadruplex structure in the bcl-2 promoter [21]. To
explore the reason underlying these repressive effects of SYUIQ-
FM05 on WT1's binding to DNA, the binding abilities of SYUIQ-
FM05 to ds59 or ZFKTS were examined. UV titration was per-
formed to investigate the binding properties of SYUIQ-FM05 to the
Pu59 region (including Pu59, Py59, and ds59) and a random du-
plex DNA (Fig. 5). The spectral parameters of the UV titration assay
are listed in Table 1. The binding constants obtained from UV ti-
tration indicated that SYUIQ-FM05 could effectively bind to Pu59
(G-quadruplex forming sequence) and ds59, with similar binding
constants 1.83107 and 1.23107 M1, respectively, but ex-
hibited moderate binding ability to Py59 and random duplex.
However, the ITC assay showed no obvious binding between
ZFKTS and SYUIQ-FM05 (Fig. S5). Therefore, although SYUIQ-
FM05 was identiﬁed as a G-quadruplex ligand, it could still bind to
ds59 DNA. The interaction with Pu59 region might be a major
reason for blocking the binding of the WT1 zinc ﬁnger.
CD spectroscopy is useful in monitoring DNA conformational
changes induced by the interaction of compounds. CD spectro-
scopy was used to further study the change in the secondary
structure of the bcl-2 Pu59 region induced by SYUIQ-FM05. The CD
spectra of ds59 (Pu59 annealed with C-rich complementary strand
sequence Py59) showed a double-strand signal with a positive
peak at around 270 nm (Fig. 6A). The titration of SYUIQ-FM05 led
to a decrease of this peak together with a slight shift to 265 nm in
a dose-dependent manner, indicating that SYUIQ-FM05 could in-
teract with ds59 and might change the conformation of the duplex
oligomer. Remarkably, the positive peak on 265 nm was a typical
signal of the G-quadruplex structure. EMSA, a convenient method
to determine DNA conformational changes, was used to further
identify the interaction between SYUIQ-FM05 and bcl-2 ds59. As
shown in Fig. 6B, the duplex-strand oligomer ds59 migrated
slower and in a dose-dependent manner in the presence of SYUIQ-
FM05. This ﬁnding may have been caused by the DNA conforma-
tional change. However, the ds59 did not migrate after the addi-
tion of EB, indicating that the migration was not due to DNA in-
tercalation. Instead, it was due to the change in DNA conformation.
We further identiﬁed whether this conformational change was
due to the formation of G-quadruplex, however, the binding
abilities of BG4 to both Pu59 and ds59 were similar after the ad-
dition of SYUIQ-FM05 (Fig. S2B).
4. Discussion
The high correlation between wt1 and bcl-2 in cancer cells and
the prognostic relevance of the coexpression of both genes in AML
Fig. 4. Blocking of WT1 binding by SYUIQ-FM05. A. Different oligomers (1.5 μM) were incubated with 3 μM of the puriﬁed ZFKTS protein and SYUIQ-FM05 at varying
concentrations and separated by 8% PAGE. B. Ch-IP–PCR products of immunoprecipitation. HL-60 cells were treated with 0.2 μM SYUIQ-FM05 for 24 h, with DMSO used as
control. The PCR product was ampliﬁed by primers occupying the 1443 to 1636 region of the bcl-2 promoter. The binding of RNA polymerase II was used as the positive
control, whereas the binding of IgG was used as the negative control. The binding of WT1 to the other WT1 target gene Pecam-1 was also used as a positive control.
Table 1
Spectral properties of UV titration.








Pu59 433 445 64.97 12 1.83107
Py59 433 440 50.58 7 4.84106
ds-Pu59 433 441 63.27 8 1.23107
Random 433 440 45.31 7 2.57106
Y.-X. Xiong et al. / Biochemistry and Biophysics Reports 5 (2016) 346–352350[20] compelled us to investigate the regulatory role of WT1 toward
the bcl-2 gene promoter by blocking WT1's binding by a small
molecule. We identiﬁed a compound named SYUIQ-FM05 that can
fulﬁll this blocking role. This study was the ﬁrst attempt to inter-
fere with WT1's binding to the bcl-2 promoter by a G-quadruplex
ligand. This is a new strategy for eliminating cancer cells besides
the knockdown of WT1 or BCL-2 by antisense oligomers, which
has shown good outcomes in AML treatment [6,25].
Considering that WT1 could bind to double-stranded con-
servative sites but not the corresponding G-quadruplex structure,
a series of G-quadruplex ligands were screened with the objective
of blocking the binding of WT1 to the bcl-2 promoter (data not
shown). Among these ligands, a quindoline derivative (SYUIQ-
FM05) showed the strongest repression ability. Further studies
showed that the repressive effect of SYUIQ-FM05 resulted fromFig. 5. UV–vis absorption spectra of 30 μM SYUIQ-FM05 in the presence of increasin
increasing the DNA concentration. The inset is a plot of [DNA]/(εa  εf) versus [DNA].binding to the ds59 region but not the ZFKTS. SYUIQ-FM05 re-
portedly stabilizes G-quadruplex structures in the Pu39 region,
thereby down-regulating P1 promoter activity, reducingg amounts of DNA. [DNA]¼0–5 μM. The arrow shows the spectral change upon
Fig. 6. The interaction between SYUIQ-FM05 with double-stranded Pu59. A. CD spectra of 5 μM double-stranded Pu59 induced by SYUIQ-FM05. The arrow indicates the
spectral change with increasing compound concentration; r represents the molar ratio (compound/DNA). B. EMSA gel image for ds59 under different compound con-
centrations. A ds59 concentration of 1.5 μM was used in each sample, incubated with or without the compound at 37 °C for 1 h, and separated by 16% PAGE.
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the apoptosis of HL-60 cells [26]. SYUIQ-FM05 was previously
shown to possess a high binding afﬁnity to the bcl-2 G-quadruplex
(with a KD value of 32 nM) and moderate binding to duplex DNA
(with a KD value of 269 nM). These observations indicated that
either the G-quadruplex or the duplex in the Pu59 region can be
recognized by SYUIQ-FM05. When SYUIQ-FM05 interacted with
ds59, CD and EMSA results showed that the conformation of ds59
was altered. However, the speciﬁc secondary structure remained
unknown. Overall, WT1 binding may be repressed by SYUIQ-FM05
either by stabilizing the G-quadruplex or interacting with the
double strand Pu59. Given the effective interaction between
SYUIQ-FM05 and the GC-rich double-strand region, further in-
vestigations on whether SYUIQ-FM05 could block the binding of
other zinc ﬁnger transcription factors, such as SP1, MAZ and ZF5
are needed. We were not able to identify the kinds of secondary
structure induced by SYUIQ-FM05 because we were limited by
experimental technique.
In conclusion, our results showed that SYUIQ-FM05 could in-
teract with the double-stranded Pu59 region of bcl-2 and change
the DNA conformation to block the binding of WT1. This phe-
nomenon may also be another reason for the down-regulated bcl-
2 expression and apoptosis of HL-60 cells. Blocking the binding of
WT1 is a promising new approach for drug design in cancer
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